ARDX · XBRL financial data

Ardelyx financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ARDX's year ends in late December)

In thousands of dollars	FY 2020Feb 28, 2021	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	10,097	52,158	124,456	333,615	407,320
Cost of revenue	—	1,000	4,117	—	—	—
Cost of goods and services sold	—	1,000	4,117	17,795	50,556	39,537
Research and development	—	91,140	35,201	35,536	52,317	71,527
Selling, general and administrative	—	72,303	76,599	134,401	258,692	337,233
General and administrative	—	72,303	76,599	—	—	—
Operating income (loss)	—	(154,346)	(63,759)	(63,276)	(27,950)	(40,977)
Interest expense	—	4,502	3,400	4,950	13,006	20,102
Income tax expense (benefit)	—	4	8	547	266	969
Net income (loss)	—	(158,165)	(67,207)	(66,067)	(39,136)	(61,599)
Earnings per share, basic USD per share	—	(1.52)	(0.42)	(0.30)	(0.17)	(0.26)
Earnings per share, diluted USD per share	—	(1.52)	(0.42)	(0.30)	(0.17)	(0.26)
Weighted average shares, basic thousands of shares	—	104,206	158,690	219,331	235,233	241,034
Weighted average shares, diluted thousands of shares	—	104,206	158,690	219,331	235,233	241,034

Fiscal years (ARDX's year ends in late December)

In thousands of dollars	FY 2020Feb 28, 2021	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	—	72,428	96,140	21,470	64,932	67,999
Marketable securities	—	44,261	27,769	162,829	185,168	196,690
Accounts receivable	—	502	7,733	22,031	57,705	71,848
Inventory	—	0	28,346	49,487	91,184	123,107
Prepaid and other current assets	—	16,458	5,112	8,408	11,096	13,566
Total current assets	—	133,649	153,603	246,111	356,452	382,317
Property and equipment, net	—	2,362	1,223	1,009	1,495	2,184
Right-of-use asset	—	12,752	9,295	5,589	2,380	4,795
Total assets	—	149,913	190,066	297,579	435,754	501,604
Accounts payable	—	4,277	10,859	11,138	16,000	19,235
Current portion of long-term debt	—	32,264	—	—	—	—
Total current liabilities	—	52,821	65,603	50,393	77,830	88,605
Lease liability, non-current	—	9,748	5,855	1,725	1,023	3,641
Total liabilities	—	67,296	91,737	130,763	262,465	334,655
Accumulated deficit	—	(712,930)	(780,137)	(846,204)	(885,340)	(946,939)
Total stockholders' equity	—	82,617	98,329	166,816	173,289	166,949
Total liabilities and equity	—	149,913	190,066	297,579	435,754	501,604
Common shares outstanding (cover page) thousands of shares	98,680	130,294	206,493	232,686	238,356	245,247

Fiscal years (ARDX's year ends in late December)

In thousands of dollars	FY 2020Feb 28, 2021	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	(158,165)	(67,207)	(66,067)	(39,136)	(61,599)
Stock-based compensation	—	12,039	10,750	13,530	37,381	48,962
Depreciation and amortization	—	2,807	1,144	1,292	2,063	3,059
Net cash from operating activities	—	(152,551)	(70,044)	(89,717)	(44,809)	(42,483)
Purchases of property and equipment	—	1,867	55	344	1,011	1,492
Net cash from investing activities	—	50,948	18,415	(131,248)	(18,318)	(8,959)
Proceeds from issuing common stock	—	101,146	71,625	119,236	0	0
Net cash from financing activities	—	82,999	75,341	146,295	106,589	54,509
Net change in cash	—	(18,604)	23,712	(74,670)	43,462	3,067

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Ardelyx	46,317	127,655	2,171*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	129,467	199,878	71,323*	32.6M	—	Q2 FY26 10-QJun 30, 2026
CorMedix	256,692	101,931	86,237*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Viridian Therapeutics	172,860	25,752	(92,773)*	113.6M	9.0 quarters	Q3 FY26 10-QSep 30, 2026
Akebia Therapeutics	155,548	49,128	3,525*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Neogen	172,000	222,800	12,900	218.3M	—	Q1 FY27 10-QAug 31, 2026
Intellia Therapeutics	106,128	7,659	(83,113)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Geron	62,643	57,480	(15,827)*	642.5M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	45,792	83,699	46,367*	134.0M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.